In a world first, researchers from The Australian National University (ANU) have shown previously ignored rare genetic mutations are a major cause of lupus.
Patent holder Corbus Pharmaceuticals is putting the drug, branded Resunab, through its clinical paces.
Ajulemic acid (AJA, CT‐3, IP‐751, JBT‐101, anabasum) is a first‐in‐class, synthetic, orally active, cannabinoid‐derived drug that preferentially binds to the CB2 receptor and is non psychoactive.
In preclinical studies, and in Phase 1 and 2 clinical trials, AJA showed a favorable safety, tolerability, and pharmacokinetic profile. It also demonstrated significant efficacy in preclinical models of inflammation and fibrosis.
More than 30 years ago while studying to be a veterinarian, Chris Goodnow became fascinated with autoimmune diseases. The interest was cemented when his mother was diagnosed with lupus...